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Abstract 
Quantification of sulfated polysaccharides in urine samples is relevant to pharmacokinetic 
studies in drug development projects and to the non-invasive diagnosis and therapy 
monitoring of mucopolysaccharidoses. The Heparin Red Kit is a particularly simple and user 
friendly fluorescence assay for the quantification of sulfated polysaccharides and has 
recently emerged as a novel tool for the monitoring of their blood levels during 
pharmacokinetic studies in clinical trials. The standard protocol for the blood plasma matrix 
is, however, not suited for urine samples due to matrix interference. The present study 
identifies inorganic sulfate as the interfering component in urine. The sulfate level of urine is 
typically 1-2 orders of magnitude higher compared with the blood plasma level. Addition of 
either hydrochloric acid or magnesium chloride counteracts sulfate interference but still 
enables sensitive detection of sulfated polysaccharides such as heparin, heparan sulfate and 
dermatan sulfate at low microgramm per milliliter levels. This study extends the application 
range of the Heparin Red Kit by a simple modification of the assay protocol to the direct 
quantification of various sulfated polysaccharides in human urine. 
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Introduction 
Sulfated polysaccharides are complex biomacromolecules with a wide variety of biological 
activities. They comprise both approved drugs, such as the widely used anticoagulant 
heparin, and various drug candidates in preclinical or clinical development. Due to their 
inherent structural heterogeneity, quantification of sulfated polysaccharides in biological 
matrices is a challenging task. In the clinical setting, heparin blood levels are quantified by 
the antithrombin-mediated effect on coagulation or on specific coagulation factors. Such 
assays can not be readily transferred to other biological matrices. Heparin quantification in 
urine, for instance, is achieved by time consuming and challenging protocols that involve 
either radiolabeling [1, 2] or the isolation of heparin followed by colorimetry, possibly 
including electrophoresis [3, 4]. Depending on the analytical method, recovery of injected 
heparin doses in urine between 1 and 39 weight % were desribed. One study [4] has 
identified in urine in approximately 1:1 ratio both unchanged heparin and a partially 
desulfated metabolite in which the average sulfation per monosaccharide is reduced from 
1.29 to 0.99. Recently there has been a renewed interest in heparin formulations for oral 
delivery [5, 6], and quantification of excreted heparin in urine is part of the pharmacokinetic 
analysis.[7] Urinary levels between 0,2 and 4 µg/mL have been reported after oral uptake of 
a 1000 U heparin / kg body weight dose. [7]  Urine levels of endogeneous sulfated 
polysaccharides (glycosaminoglycans, respectively) are elevated in several types of 
mucopolysaccharidoses, a group of genetic disorders caused by deficiency of enzymes 
needed to degrade the polysaccharides. Depending on MPS type, urinary levels of heparan 
sulfate and dermatan sulfate, for instance, can be ten to hundreds of times higher than the 
normal range.[8, 9] Dye-based methods (Berry spot test and dimethylmethylene blue 
photometry [10]) that determine total urinnary glycosaminoglycans are routinely applied to 
the initial diagnostic screening for MPS. Quantification of specific polysaccharides in urine 
supports identification of the MPS type and therapy monitoring but requires more 
sophisticated analytical methodology such as HPLC-MS.[8,9]  
Heparin Red is a new analytical tool for the direct detection of sulfated polysaccharides in 
complex biological matrices by a simple mix-and-read assay. It is a polycationic fluorescent 
dye (scheme 1) that forms non-fluorescent aggregates with the polyanionic target (scheme 
2).[11, 12] Two assays based on Heparin Red have become commercially available [13] and 
been applied to the quantification of a variety of sulfated polysaccharides and biological 
matrices.[14-21] The Heparin Red Kit is of particular use for detections in a blood plasma 
matrix and has emerged as a new tool for pharmacokinetic studies of non-anticoagulant 
heparins that are difficult to quantify by other methods.[14, 22, 23] The standard protocol of 
this assay for plasma samples is, however, not suited for urine due to significant matrix 
 
interference. Another assay Heparin Red Ultra was reported to detect heparin in urine but is 
not sensitive to polysaccharides with a lower sulfation degree.[21]   
 
                   
Scheme 1. Major repeating disaccharide units of the sulfated polysaccharide heparin (left). 
Structure of the polycationic fluorescent probe Heparin Red (right).   
 
 
Scheme 2. Schematic representation of fluorescence quenching of the molecular probe Heparin Red 
in the presence of a polyanionic sulfated polysaccharide.     
 
In this contribution, we identify the interference of the Heparin Red Kit in urine samples as 
inorganic sulfate and describe simple modifications of the assay protocol to overcome this 
interference. The adapted protocol enables not only the detection of heparin but also of less 
sulfated polysaccharides such as dermatan sulfate and heparan sulfate in urine. 
 
Materials and Methods 
Instrumentation 
Fluorescence measurements 
Fluorescence was measured with a microplate reader Biotek Synergy Mx (Biotek  
Instruments, Winooski, VT, USA), excitation at 570 nm, emission recorded at 605 nm,  
spectral band width 17 nm, gain 100, read height of 8 mm. Black 96 well microplates for 
fluorescence, polystyrene, Item No 655076, were purchased from Greiner Bio-One GmbH, 
Frickenhausen. 
 
 
pH measurements 
The pH value in DMSO-water 4:1 mixtures was measured with a glass electrode (InLab® 
Micro, SemiMicro, Mettler Toledo) that was freshly calibrated using aqueous buffers pH 4.0 
and pH 7.0.  
 
Reagents 
 
Heparin Red® Kit 
The Heparin Red Kit was a gift from Redprobes UG, Münster, Germany. 
  
Sulfated polysaccharides 
Unfractionated heparin sodium salt from porcine intestine mucosa was purchased from 
Sigma-Aldrich GmbH, Steinheim, product number H5515, Lot SLBK0235V. Heparan sulfate 
from porcine mucosa, highly purified fractions I and III (Cat No GAG-HS I and GAG-HS III) 
were purchased from Iduron Ltd, Cheshire, UK. Dermatan sulfate sodium from porcine 
mucosa, product number C3788 (referred to as chondroitin sulfate B), batch SLBM9912V, 
was purchased from Sigma-Aldrich (Taufkirchen, Germany). According to the certificate of 
analysis of the provider, the batch contains 9% water, 6.5% S and 8.6% Na. 
 
Urine 
Urine 1 is a commercially available pooled normal human urine Katalog Nr: IR100007P-
1000, Lot 17317, from Innovative Research. Urine 2 is a pool urine from three healthy 
donors.  Urines were stored at -20°C and thawed before use. Spiked urine samples were 
either used directly after spiking, or stored at -20°C and thawed prior to use. 
 
Other  
Aqueous solutions were prepared with HPLC grade water purchased from VWR, product No 
23595.328. Inorganic salts were >99% pure. 18-crown-6 was purchased from Sigma Aldrich, 
product number 186651, Lot 0000041795. Hydrochloric acid (1.0 M), product number 35328, 
Lot # SZBF2050V, was purchased from Sigma-Aldrich (Taufkirchen, Germany). 
 
Assays 
 
Heparin Red® Kit, standard protocol 
The protocol of the provider for a 96-well microplate assay with plasma samples was 
followed. Mixtures of Heparin Red solution and 9 mL Enhancer solution (volume ratio 1:90) 
 
were freshly prepared. Eventually (figure 1), 59,4 µL of a 1 M sodium acetate solution 
replaced the same volume of Enhancer solution to achieve a 6.6 mM sodium acetate 
concentration in the reagent mixture. 20 µL of the sample was pipetted into a microplate well, 
followed by 80 µL of the Heparin Red – Enhancer mixture. For sample numbers > 10, a 12-
channel pipette was used for addititon of the Heparin Red – Enhancer solution. The 
microplate was introduced in the fluorescence reader and mixing was performed using the 
plate shaking function of the microplate reader (setting “high”, 3 minutes). Immediately after 
mixing, fluorescence was recorded within 1 minute. 
 
Heparin Red® Kit, protocol modified fo urine samples by addition of HCl or MgCl2 
The protocol of the provider for a 96-well microplate assay with plasma samples was 
modified as follows: To a freshly prepared mixture of Heparin Red solution and either 8.858 
mL or 8.775 mL Enhancer solution (volume ratio 1:90), either 142 µL of a 1 M HCl or 225 µL 
of a 2 M MgCl2 solution was added to achieve a 15.6 mM HCl concentration or 50 mM MgCl2 
concentration, respectively,  in the reagent mixture.  20 µL of the sample was pipetted into a 
microplate well, followed by 80 µL of the reagent mixture. For sample numbers > 10, a 12-
channel pipette was used for addititon of the Heparin Red – Enhancer solution. The 
microplate was introduced in the fluorescence reader and mixing was performed using the 
plate shaking function of the microplate reader (setting “high”, 3 minutes). Immediately after 
mixing, fluorescence was recorded within 1 minute. 
 
Barium sulfate precipitation  
The urine sample was mixed with 9 vol% of a 100 mM BaCl2 solution and kept in a 1.5 mL 
Eppendorf tube  at ambient temperature for 10 minutes. The mixture was then centrifuged at 
10000 rpm for 5 minutes.  
 
Sulfate assay 
Sulfate concentrations in urine were determined by the commercial Sulfate Test 101812 
(Merck KGaA, Darmstadt), based on photometric turbidity measurement after precipitation as 
BaSO4. Instructions of the provider were followed. A 100-fold dilution of the urine sample was 
applied.  
 
 
 
 
 
 
 
Results and discussion 
Sulfate interferes with the Heparin Red assay 
A preliminary screening of the abundant inorganic ions in urine (table 1) revealed that only 
sulfate (SO42-) quenches Heparin Red fluorescence significantly. From a refined analysis of 
sulfate interference, we conclude that not only the sulfate concentration but also the pH of 
the assay mixture strongly influences fluorescence quenching. The assay medium is a 
mixture of about 76 vol% DMSO, 4 vol% acetic acid and 20 vol.% aqueous sample. There 
are several literature reports [24-27] about reproducible pH measeruments with a glass 
electrode in a DMSO water 80:20 mixture. We have therefore applied this technique to pH 
determination of the assay mixtures.  
Compound Reference range 
for urine [28] * 
Na+ 27-167 mM 
Mg2+ 2.5-8.5 mM 
Ca2+ 2.5-7.5 mM 
K+ 23-67 mM 
Cl- 67-167 mM 
H2PO4-/HPO42-  9-28 mM ** 
SO42- 
12 mM 
(5-31 mM) *** 
 
Table 1. Reference ranges of the major inorganic ions present in human urine (usually defined as the 
set of values 95% of the normal population falls within). * Concentration in urine derived from values 
for excretion over 24 hours [28], assuming a daily urine volume of 1.5 L [29]. ** This concentration 
value refers to the sum of H2PO4-and HPO42- since the pKa of H2PO4- is 6.8 and both species may 
be present within the reference pH range 4.5-8 [28] of urine. *** Sulfate determination is not part of 
routine urinalysis. 12 mM is the average sulfate concentration in normal urine from 110 healthy 
donors, by ion chromatography.[30] 5-31 mM relates to the reference range given by several clinical 
laboratories.[31, 32] Sulfate excretion is highly dependent on dietary protein uptake.[33] 
Figure 1 displays the effect of sulfate concentration on Heparin Red fluorescence. The pH of 
the assay mixture was kept approximately constant at 6.0 by adding 6.6 mM sodium acetate 
to the reagent solution, thus creating an “acetate buffer” (although at a large excess of acetic 
acid). This mimics the effect of basic urinary buffer components such as HPO42-/H2PO4- that 
are expected to react with acetic acid and form acetate upon mixing the reagent solution with 
the urine sample. It is obvious from the high fluorescence in the absence of sulfate that the 
 
acetate anion itself does not interfere with the assay. When the assay mixture is prepared 
with a sample of urine 1, the resulting pH 6.0 matches that of the acetate buffered medium 
applied for the detections in figure 1.       
 
Figure 1. Fluorescence response of Heparin Red to aqueous samples containing Na2SO4 in varying 
concentration. The standard protocol for the Heparin Red Kit was modified by adding 6.6 mM sodium 
acetate to the Enhancer solution (see Materials and Methods). Manually performed microplate assay. 
Excitation at 570 nm, fluorescence emission at 605 nm. Averages of duplicate determinations. The pH 
of the acetate-buffered assay solution at c(sulfate) = 0 mM was 6.0. The pH of the acetate-buffered 
assay solution at c(sulfate) = 2 mM was 6.0. 
 
The effect of pH variation of the assay solution at constant sulfate concentration of 2 mM is 
shown in figure 2. If a sample containing 2 mM KHSO4 is mixed with the reagent solution, pH 
4.8 is measured in the assay solution and no fluorescence quenching of Heparin Red 
observed. The pH of this mixture is similar to that in the absence of KHSO4, suggesting that 
HSO4-  dissociates only to a minor extent into protons and SO42-. These observations support 
the idea that the HSO4- monoanion is not interfering with the assay. The pH of the assay 
solution was gradually increased by adding NaOH to the KHSO4 sample prior to mixing with 
the reagent solution. This went along with a decrease of dye fluorescence due to conversion 
of HSO4- to SO42-. A mixture of 2 mM KHSO4 and 10 mM NaOH is expected to not only 
generate 2 mM SO42- in the sample but also an acetate/acetic acid buffer medium in the 
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assay solution comparable to that described for figure 1. This is confirmed by measuring pH 
6.0, identical to that of the assay solution of figure 1 at 2 mM sulfate.   
 
 
Figure 2. Fluorescence response of Heparin Red to aqueous samples containing 2 mM sulfate at 
varying pH of the assay solution (obtained by mixing the Enhancer-Heparin Red reagent solution with 
the sample). The standard protocol for the Heparin Red Kit (see Materials and Methods) was applied. 
Variation of pH was achieved by adding varying concentrations of NaOH (0 mM at pH 4.8 to 10 mM at 
pH 6.0) to an aqueous KHSO4 sample.  Manually performed microplate assay. Excitation at 570 nm, 
fluorescence emission at 605 nm. Averages of duplicate determinations.  
 
Note that the pKa values of acids that form anionic conjugated bases are shifted to higher 
values in DMSO:water 80:20 relative to aqueous solution due to less effective anion 
solvation by the organic solvent . The pKa of acetic acid in DMSO:water 80:20 is 8.0 [25, 34], 
vs 4.8 in aqueous solution. For HSO4-, we also expect a significant pKa increase relative to 
the value 1.9 for aqueous solution.  We measured pH 6.7 for a 1:1 mixture of KHSO4 and 
Na2SO4 (5 mM : 5 mM) in DMSO:water 80:20, suggesting that the value corresponds to the 
pKa of HSO4-  in this medium.   
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Sulfate is the interfering component in urine 
Fig. 3 compares the fluorescence of Heparin Red with human plasma, phosphate buffered 
saline (PBS) and urine 1 samples, following the standard assay protocol for the Heparin Red 
Kit. Only the urine matrix triggers a strong fluorescence response of the dye so that this 
matrix is not well suited for the detection of sulfated polysaccharides.  
 
Figure 3. Fluorescence response of Heparin Red to a human plasma, a phosphate buffered saline 
(PBS) and a urine 1 sample, following the standard protocol for the Heparin Red Kit (see Materials and 
Methods).   Manually performed microplate assay. Excitation at 570 nm, fluorescence emission at 605 
nm. Averages of duplicate determinations.   
Sulfate in the urine 1 sample was quantified by a commercial assay that detected  4.7 mM, a 
concentration at the lower limit of the reference range for urine (table 1). Strong fluorescence 
quenching at this sulfate concentration is in line with the data in figure 1. The urine level of 
sulfate (table 1) is 1-2 orders of magnitude higher than the plasma or serum level which is 
normally in the range 0.25 to 0.4 mM [35-37]. This readily explains why sulfate interference is 
not relevant to plasma samples since this concentration does not trigger fluorescence 
quenching of Heparin Red (figure 1, figure 3).   
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
Human Plasma PBS Urine 1
flu
or
es
ce
nc
e in
te
ns
ity
 
Sulfate interference in urine is further substantiated by its removal by precipitation as BaSO4,    
through addition of 10 mM  barium chloride to the urine sample and removal of the 
precipitate by centrifugation. After this pretreatment, the urine sample does no longer quench 
the fluorescence of Heparin Red, see figure 4 B. It is unlikely that fluorescence recovery is 
triggered by excess barium chloride (rather than sulfate) since subsequent masking of Ba2+ 
by the macrocyclic ligand 18-crown-6 (100 mM) does not reduce fluorescence intensity 
(figure 4 C). Moreover, if 18-crown-6 is added to the urine sample prior to BaCl2, BaSO4 
precipitation is largely prevented by complexation of the metal ion, resulting in significant 
interference by sulfate that has not been removed from the sample (figure 4 D). An additional  
control experiment using 20 mM NaCl confirmed that the chloride of the 10 mM BaCl2 
additive has no effect on fluorescence response to the urine sample (data not shown).  
 
Figure 4. Fluorescence response of Heparin Red to A)  urine 1; B) urine 1 + 10 mM BaCl2, after 
removal of precipitate; C) solution B, removal of precipitate + 100 mM 18-crown-6; D) urine 1 + 100 
mM 18-crown-6 + 10 mM BaCl2, very minor precipitate; E) urine 1 + 100 mM 18-crown-6. Standard 
protocol for the Heparin Red Kit was followed (see Materials and Methods). Manually performed 
microplate assay. Excitation at 570 nm, fluorescence emission at 605 nm. Averages of duplicate 
determinations.   
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Sulfate interference is overcome by modifiying the Heparin Red assay protocol 
 
Considering the strong pH dependence of sulfate interference of the Heparin Red assay 
(figure 2), we established addition of hydrochloric acid to the assay solution as a strategy to 
overcome sulfate interference and enable the detection of sulfated polysaccharides in urine 
samples. The monoanionic sulfate ester moieties in sulfated polysaccharides are much less 
basic than the SO42- dianion. We therefore anticipated selective protonation of SO42- to HSO4- 
without affecting the sulfate ester groups by proper control of the pH of the assay solution. In 
practice, the standard assay protocol was modified simply by adding 15.6 mM HCl to the 
reagent mixture, prior to its application to the sample (see Materials and Methods for details). 
The presence of HCl effected a much higher fluorescence with urine samples, comparable to 
that of aqueous or PBS samples. With the modified protocol, not only heparin, having an 
average charge density of -1.7 per monosaccharide and a sulfation degree of 1.2 per 
monosaccharide, but also structurally related polysaccharides with a lower sulfation degree 
(table 2) such as heparan sulfate and dermatan sulfate can be recovered as spikes in urine 
samples (figure 5). Moreover, the response curves display good linearity within the 
concentration range 0-10 µg/mL polysaccharide.  
 
 
 
 
 
  
 
Figure 5. Fluorescence response of Heparin Red to samples of urine 1 spiked with heparin (H), 
heparan sulfate fraction I (HS I), heparan sulfate fraction III (HS III), and dermatan sulfate (DS) in 
varying concentrations. A modifed protocol for the Heparin Red Kit including addition of 15.6 mM HCl 
to the reagent mixture was followed (see Materials and Methods for details). Manually performed 
microplate assay. Excitation at 570 nm, fluorescence emission at 605 nm. Averages of duplicate 
determinations.   
The pH of the HCl containing assay solution after mixing with the urine sample was 3.1, and 
in line with the results outlined in figure 2 an interference by urinary sulfate is not expected 
under these conditions due to its conversion to non-interfering HSO4-.  
The sensitivity of the assay for a specific sulfated polysaccharide depends on the sulfation 
degree of the latter (table 2). The higher the sulfation, the less polysaccharide is needed to 
form a charge neutral complex with Heparin Red [12], and the more sensitive the assay is. 
Considering pKa 8 for acetic acid in the DMSO water 80:20 assay solution [25, 34], we 
assume protonation of the carboxylate groups of the analytes (scheme 1). Therefore, only 
the sulfate groups remain for electrostatic binding to polycationic Heparin Red (scheme 1, 2).  
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Sulfated polysaccharide Average sulfation 
per monosaccharide 
Average charge density 
per monosachharide 
Ref 
H (heparin)  1.2 -1.7 [38] 
DS (dermatan sulfate) 0.55 -1.05 [18] 
HS I (heparan sulfate fraction I) 0.38 -0.88 [15] 
HS III (heparan sulfate fraction III) 0.88 -1.38 [15] 
Table 2. Average sulfation and charge (including carboxylate groups) per monosaccharide of sulfated 
polysaccharides tested with the Heparin Red assay in figure 5.    
Different pool urine samples (urine 1, urine 2) show very similar response curves, as 
exemplified by detection of a HS III spike (figure 6). Moreover, increasing the HCl 
concentration in the reagent mixture from 15.6 to 30 mM does not significantly change the 
response curve for HS III (data not shown). Apparently, 15.6 mM HCl both compensates the 
buffer capacity and protonates interfering sulfate in the urine samples used in this study.   
 
Figure 6. Fluorescence response of Heparin Red to different pool urine samples, urine 1 and urine 2,  
spiked with HS III. A modifed protocol for the Heparin Red Kit including addition of 15.6 mM HCl to the 
reagent mixture was followed (see Materials and Methods for details). Manually performed microplate 
assay. Excitation at 570 nm, fluorescence emission at 605 nm. Averages of duplicate determinations.   
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We have previously reported the detection of heparin in urine by Heparin Red Ultra, another 
commercially available assay.[21] Heparin Red Ultra does, however, not respond to less 
sulfated polysaccharides such as dermatan sulfate. Human serum albumin (HSA) that may 
be present in trace amounts in urine interferes with the assay. We have interpreted this by 
conversion of HSA to a polycationic strong heparin binder in the acidic reaction medium of 
the assay, masking the response of Heparin Red.[21] HSA spikes have a comparable 
masking effect if the modified Heparin Red Kit protocol with addition of HCl is applied (figure 
8).  
We have therefore evaluated another protocol modification, the addition of 50 mM MgCl2 to 
the reagent solution [20], for detection of sulfated polysaccharides in urine samples. MgCl2 
also overcomes the strong fluorescence quenching by urinary sulfate and enables the 
sensitive detection of the polysacchairdes listed in table 2 (figure 7). The pH 4.5 of the 50 
mM MgCl2 containing reagent solution after mixing with water (80:20) is the same as in the 
absence of MgCl2, suggesting that masking of sulfate is not a pH effect but due to direct 
binding of the lewis-acidic diavalent magnesium ion to sulfate. In contrast to the HCl 
containing medium, detections in the MgCl2 medium are much less affected by trace 
amounts of HSA (figure 8). In the general population, the average urinary HSA concentration 
is 5 µg/mL, and less than 25% have urinary HSA levels > 15 µg/mL (the values were derived 
from mg HSA / g creatinine data [39], asuming an average urinary creatinine concentration in 
the general population of 1,3 g / L [40]). HSA in urine is commonly determined by 
immunoassays and measured concentrations must not essentially correlate with the effect of 
the HSA spikes in figure 8 (using a commercial HSA sample isolated from human serum)  
since different molecular forms of albumin may be present in urine.[41]   
 
  
Figure 7. Fluorescence response of Heparin Red to samples of urine 1 spiked with heparin (H), 
heparan sulfate fraction I (HS I), heparan sulfate fraction III (HS III), and dermatan sulfate (DS) in 
varying concentrations. A modifed protocol for the Heparin Red Kit including addition of 50 mM MgCl2 
to the reagent mixture was followed (see Materials and Methods for details). Manually performed 
microplate assay. Excitation at 570 nm, fluorescence emission at 605 nm. Averages of duplicate 
determinations. 
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Figure 8. Effect of human serum albumin (HSA) spikes in varying concentration on the fluorescence 
response of Heparin Red to samples of urine 1 containing 4 µg/mL heparin. Modifed protocols for the 
Heparin Red Kit including either addition of 50 mM MgCl2 or addition of 15.6 mM HCl to the reagent 
mixture was followed (see Materials and Methods for details). Manually performed microplate assay. 
Excitation at 570 nm, fluorescence emission at 605 nm. Averages of duplicate determinations. 
 
The presence of endogeneous sulfated polysaccharides in urine should be considered as a 
potential cause of background signal in the Heparin Red assay. According to a recent LCMS 
analysis [42], the overall sulfated polysaccharide concentration in human urine averages to 
about 4.8 µg/mL and is a mixture of 83 % chondroitin sulfates (CS, including dermatan 
sulfate) and 17 % heparan sulfate. Individual levels are, however,  highly variable and can 
range from <1 µg/mL to 10 µg/mL. Average sulfation per monosaccharide is 0.32 for urinary 
CS and 0.35 for urinary HS (derived from the data in [42]). This corresponds to a lower 
sulfation compared with any sulfated polysaccaride investigated in the present study (table 
2), and endogeneous urinary CS and HS might be relatively poor targets for the Heparin Red 
assay. Fluorescence of the unspiked pool urine samples in figure 6 is comparable to that of a 
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phosphate buffered saline (PBS) sample, suggesting that these samples do not contain 
detectable levels of endogeneous sulfated polysaccharides. It should nevertheless be 
considered that even normal urine may contain CS and HS levels that generate a 
background signal.  
 
HS and DS are urinary biomarkers for most types of mucopolysaccharidoses (MPS). In MPS 
type I-III, 100-200 times higher than normal urinary HS levels were determined by HPLC 
analysis.[8] A 6-10fold elevation of DS was reported for children with MPS type I and VI.[9] 
The modified Heparin Red assay as described in Figure 5 and 8 should readily detect such 
elevated overall concentrations of sulfated polysaccharides in the urine of MPS patients. The 
diagnostic value would be stronger if concentrations of individual sulfated polysaccharides 
can be determined. We plan therefore to refine the method by implementing selective 
enzymatic digestion of one polysaccharide in HS/DS mixtures. 
  
Conclusion  
 
Quantification of sulfated polysaccharides in urine samples is relevant to pharmacokinetic 
studies in drug development projects and to the non-invasive diagnosis and therapy 
monitoring of mucopolysaccharidoses. The Heparin Red fluorescence assay is a particular 
simple and user friendly analytical method for sulfated polysaccharides quantification and 
has recently emerged as a novel tool for the monitoring of their blood levels during 
pharmacokinetic studies in clinical trials. The standard protocol for the blood plasma matrix 
is, however, not suited for urine samples due to matrix interference. In this study we have 
identified inorganic sulfate (SO42-) as the interfering component in urine. The sulfate level of 
urine is usually 1-2 orders of magnitude higher compared to the blood plasma level. 
Lowering the pH of the assay solution by addition of hydrochloric acid counteracts sulfate 
interference due to protonation of dianionic sulfate to non-interfering HSO4- monoanion, but 
still enables sensitive detection of sulfated polysaccharides such as heparin, heparan sulfate 
and dermatan sulfate. Alternatively, addition of magnesium chloride to the assay solution 
overcomes sulfate interference and offers the additional advantage of largely supressing an 
interference by albumin that may be present in trace amount in urine samples. This study 
extends the application range of Heparin Red by simple modifications of the assay protocol 
to the direct quantification of various sulfated polysaccharides at low µg/mL levels in human 
urine. 
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